Helicos BioSciences has appointed Steve Lombardi as the company's chief executive officer. Lombardi, 53, succeeds Stan Lapidus, who will continue as chairman of the board of Helicos.
Znomics has named Mark A. Philip, Ph.D. as the company's new president and CEO.
HairDX named David R. Teckman as its new president and CEO.
Milestone Biosciences has named Eric P. Loukas as CEO. Current president, CEO and co-founder, Frank Jacobucci, will become president and COO.
Vincent W. Renz has joined NewCardio as its president.
Benda Pharmaceutical has appointed George Zhou as COO.
Averion International has named Peter C. Gonze as executive vice president of global business development.
Trubion Pharmaceuticals has appointed Scott Stromatt as the company's chief medical officer.
Pacific Biometrics disclosed that Mario Ehlers, MD, PhD, has resigned his position as chief medical officer of the company.
Industry veteran Gilles H. Tapolsky, Ph.D. has joined Advanced Cancer Therapeutics as chief scientific officer.
Onyx Pharmaceuticals has appointed Juergen Lasowski as its new senior vice president of corporate development.
VIRxSYS Corporation announced that Shuyuan Zhang, PhD, has joined the company as senior director of production.
Somaxon Pharmaceuticals has named Daniel Schneider to the newly-created position of vice president of sales and Joseph Merkert to the newly-created position of vice president of sales operations and managed care.
Vyteris has formed a Scientific Advisory Group. They are Russell Potts, PhD, chairperson; Richard Guy, PhD; Randy Mrsny, PhD and Stephen Silberstein, MD, FACP.
iTherX Pharmaceuticals Inc, a privately held biopharmaceutical company, today announced that it has appointed a Scientific and Clinical Advisory Board. Members of the newly formed Advisory Board include: John McHutchison, MD (Chair) Professor of Medicine, Division of Gastroenterology and Associate Director, Duke Clinical Research Institute, Duke University; Charles Rice, PhD, Professor of Virology, Rockefeller University and Director, Center for the Study of Hepatitis C; Robert Schooley, MD, Professor and Head, Division of Infectious Diseases, UCSD School of Medicine; and, Alan Perelson, PhD, Senior Fellow, Los Alamos National Laboratory.
Samuel H. Rudman has been appointed to the board of XTL Biopharmaceuticals.
Speedel has elected four of Novartis' officers to its board. They are: Dr. Raymund Breu--chief financial officer, Novartis International; Joseph Jimenez--CEO, Novartis Pharma; Jonathan Peacock--chief financial officer, Novartis Pharma; Joerg Walther--global head, legal M&A and antitrust, Novartis International.